|

Foscenvivint Clinical Trials

1 actively recruiting trial

Also known as: CBP-beta-catenin inhibitor, OP-724, PRI-724 (former name)

Pipeline

Phase 2: 1

Top Sponsors

  • Kiminori Kimura, MD1

Indications

Other1 trial

A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.